Advertisement

Clinical Rheumatology

, Volume 32, Issue 7, pp 1045–1052 | Cite as

Th17/Treg imbalance induced by increased incidence of atherosclerosis in patients with Systemic Lupus Erythematosus (SLE)

  • Zhu Mengya
  • Mo HanyouEmail author
  • Li Dong
  • Luo Xiaohong
  • Zhang Lihua
Original Article

Abstract

The objective of the study was to investigate whether the immunological factors in patients with Systemic Lupus Erythematosus (SLE) and a high incidence of atherosclerosis correlate with a Th17/Treg imbalance. All cases were recruited from the Affiliated Hospital of Guilin Medical University: a random sample of 42 cases with SLE and atherosclerosis, 39 positive control cases with SLE alone with no anomalies detected via coronary artery angiography or carotid color Doppler ultrasound examination, as well as 45 normal controls based on physical examination were included. The serum expression levels of IL-10, IL-17, IL-6, TNF-α, Th17, Th17 cell transcription factor RORγt, and Treg cell transcription factor Foxp3 were measured in each group of patients. Correlations among Th17/Treg, their secreted cell factors, transcription factors, SLE, and SLE with concurrent atherosclerosis (SLE + AS) were analyzed. The results are as follows: (1) total cholesterol and triacylglycerol levels in the SLE and SLE + AS groups were higher than those in the control group (P < 0.05 and P < 0.01); (2) serum IL-10 in the SLE + AS group was lower than the SLE and control groups; however, serum IL-17and IL-6 levels in the SLE + AS group were elevated compared to the SLE and control groups (average P < 0.01); (3) the percentage of Treg cells in the SLE + AS patients was lower than those found in the SLE and control groups; in contrast, percentages of serum Th17 cells in SLE + AS patients were higher than the SLE and control groups (average P < 0.01); (4) FoxP3 expression in the SLE + AS group was lower than levels observed in the SLE and control groups (average P < 0.05); in contrast, RORγt expression in the SLE + AS group was higher than levels found in the SLE and control groups (average P < 0.05). The abnormal balance between Th17 cells and Treg cells in SLE + AS patients has obvious implications for Th17 migration. The results suggest that Th17 cell proportion and function can be enhanced, relatively or absolutely, whereas the proportion and function of Treg cells can abate, relatively or absolutely. This imbalance may be an important reason for the high incidence of SLE with atherosclerosis.

Keywords

Atherosclerosis Regulatory T cells Systemic Lupus Erythematosus T helper cell 17 

Notes

Acknowledgments

The study was supported by grants from the Chinese National Natural Science Foundation (no. 81160376)

Disclosures

None.

References

  1. 1.
    Von Feldt JM (2008) Premature atherosclerotic cardiovascular disease and Systemic Lupus Erythematosus from bedside to bench. Bull NYU Hosp Jt Dis 66:184–187Google Scholar
  2. 2.
    Boucelma M, Haddoum F, Chaudet H et al (2011) Cardiovascular risk and lupus disease. Int Angiol 30:18–24PubMedGoogle Scholar
  3. 3.
    Sherer Y, Zinger H, Shoenfeld Y (2010) Atherosclerosis in Systemic Lupus Erythematosus. Autoimmunity 43:98–102PubMedCrossRefGoogle Scholar
  4. 4.
    Koltsova EK, Garcia Z, Chodaczek G et al (2012) Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J Clin Invest 122:3114–26PubMedCrossRefGoogle Scholar
  5. 5.
    Frieri M (2012) Accelerated atherosclerosis in Systemic Lupus Erythematosus: role of proinflammatory cytokines and therapeutic approaches. Curr Allergy Asthma Rep 12:25–32PubMedCrossRefGoogle Scholar
  6. 6.
    Scalapino KJ, Tang QB, Luestone JA et al (2006) Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol 177:1451–1459PubMedGoogle Scholar
  7. 7.
    Puddu PE, Lanti M, Menotti A et al (2001) Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio population study. Acta Cardiol 56:243–251PubMedCrossRefGoogle Scholar
  8. 8.
    Sato H, Miida T, Wada Y (2007) Atherosclerosis is accelerated in patients with long-term well-controlled Systemic Lupus Erythematosus (SLE). Clin Chim Acta 385:35–42PubMedCrossRefGoogle Scholar
  9. 9.
    Barta Z, Harrison MJ, Wangrangsimakul T et al (2010) Health-related quality of life, smoking and carotid atherosclerosis in white British women with Systemic Lupus Erythematosus. Lupus 19:231–238PubMedCrossRefGoogle Scholar
  10. 10.
    Wade NS, Major AS (2011) The problem of accelerated atherosclerosis in Systemic Lupus Erythematosus: insights into a complex co-morbidity. Thromb Haemost 106:849–57PubMedCrossRefGoogle Scholar
  11. 11.
    Petri MA, Kiani AN, Post W et al (2011) Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 70:760–765PubMedCrossRefGoogle Scholar
  12. 12.
    Kiani AN, Post WS, Magder LS et al (2011) Predictors of progression in atherosclerosis over 2 years in Systemic Lupus Erythematosus. Rheumatology (Oxford) 50:2071–2079CrossRefGoogle Scholar
  13. 13.
    Sakaguchi S (2005) Naturally arising Foxp3 expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 699:345–352CrossRefGoogle Scholar
  14. 14.
    Komiyama Y, Nakae S, Matsuki T et al (2006) IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177:566–573PubMedGoogle Scholar
  15. 15.
    Okamoto A, Fujio K, Okamura T et al (2011) Regulatory T-cell-associated cytokines in Systemic Lupus Erythematosus. J Biomed Biotechnol 463412Google Scholar
  16. 16.
    Chaudhry A, Samstein RM, Treuting P et al (2011) Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34:566–578PubMedCrossRefGoogle Scholar
  17. 17.
    Zheng Y, Danilenko DM, Valdez P et al (2006) Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:648–651PubMedCrossRefGoogle Scholar
  18. 18.
    Romagnani S, Maggi E, Liotta F et al (2009) Properties and origin of human Th17 cells. Mol Immunol 47:3–7PubMedCrossRefGoogle Scholar
  19. 19.
    Xing Q, Wang B, Su H et al (2012) Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int 32:949–958PubMedCrossRefGoogle Scholar
  20. 20.
    Robinson DS (2009) Regulatory T cells and asthma. Clin Exp Allergy 39:1314–23PubMedCrossRefGoogle Scholar
  21. 21.
    Gotsman I, Grabie N, Gupta R et al (2006) Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 114:2047–2055PubMedCrossRefGoogle Scholar
  22. 22.
    Tu H, Li Q, Xiang S et al (2012) Dual effects of statins therapy in Systemic Lupus Erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells. Atherosclerosis 222:29–33PubMedCrossRefGoogle Scholar
  23. 23.
    Svenungsson E, Fei GZ, Jensen-Urstad K et al (2003) TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 12:454–61PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2013

Authors and Affiliations

  • Zhu Mengya
    • 1
  • Mo Hanyou
    • 1
    Email author
  • Li Dong
    • 1
  • Luo Xiaohong
    • 1
  • Zhang Lihua
    • 1
  1. 1.Department of Clinical Immunology and RheumatologyThe Affiliated Hospital of Guilin Medical CollegeGuilinChina

Personalised recommendations